Italian CDMO and API producer Olon Group has acquired its compatriot HuvePharma Italia, which makes APIs and advanced intermediates via chemical synthesis, from the Huvepharma EOOD group. This is part of Olon’s strategy of growth, consolidation and expansion, both internally and through acquisitions
Italian CDMO Olon Group has announces the ongoing construction of a high potency API (HPAPI) suite at the site in Concord, Ohio, which hosts its centre of excellence for early development of APIs. This adds to the commercial-scale capabilities of sites at Segrate and Rodano, near Milan, Italy, where Olon has invested about €40 million in the last few years.
Italian CDMO Olon has opened its new R&D centre at its industrial plant and headquarters in Rodano, near Milan. This will be mainly dedicated to the development of APIs for the innovator and generic markets. It cost €10 million and will create 50 new jobs, bringing the total to 350 out of the 2,300 total.
Italian CDMO Olon Group has announced a €10 million, multi-year expansion plan for its production site in Mahad, India. This will increase its chemical synthesis capacity for intermediates and APIs by 45%, particularly for products in high demand where Olon is already the market leader.
Italian CDMO Olon has announced the start of a construction on a €22 million facility for the production of ultra-potent compounds. These are aimed for use mainly as payloads and payload-linkers for antibody-drug conjugates (ADCs) at its site at Rodano, near Milan. The facility will reach containment OEB Level 6, with a target occupational exposure level (OEL) of 10 ng/m3.
Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.
Italian firm Olon has presented its new division, Olon Biotech, which will offer CDMO services at industrial scale. These based on microbial fermentation processes using bacteria, yeast and fungi and will include high potency. It will also have proprietary products for industries including health and pharma, food, cosmetics, flavours and fragrances.
